Aequitron Medical acquires central nervous systems (CNS) sleep diagnostic range:
This article was originally published in Clinica
Electronic respiratory product manufacturer Aequitron Medical is to acquire CNS' sleep diagnostic business which has annual revenues of $7 million. The combined $6 million cash and debt transaction gives Aequitron rights to all CNS' sleep disorder diagnostic products as well as a product in development. It also gains distribution rights to CNS' Breathe Right nasal strips to professional healthcare markets. Production and staffing for the CNS products will move to Aequitron Medical's headquarters in Plymouth, Minnesota. CNS chairman and CEO Daniel Cohen says the company intends to concentrate on developing its core business - the Breathe Right product line.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.